VERA

Vera Therapeutics, Inc. Class A Common Stock

43.26

USD

VERA Earnings Reports

Positive Surprise Ratio

VERA beat 6 of 19 last estimates.

32%

Next Report

Date of Next Report

Feb 24, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$1.30

Implied change from Q3 25 (Revenue/ EPS)

+3.17%

Implied change from Q4 24 (Revenue/ EPS)

+80.56%

Vera Therapeutics, Inc. Class A Common Stock earnings per share and revenue

On Nov 05, 2025, VERA reported earnings of -1.26 USD per share (EPS) for Q3 25, missing the estimate of -1.15 USD, resulting in a -8.76% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.03% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 14 analysts forecast an EPS of -1.30 USD, with revenue projected to reach -- USD, implying an increase of 3.17% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

FAQ

What were Vera Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Vera Therapeutics, Inc. Class A Common Stock reported EPS of -$1.26, missing estimates by -8.76%, and revenue of $0.00, 0% as expectations.

How did the market react to Vera Therapeutics, Inc. Class A Common Stock's Q3 2025 earnings?

The stock price moved down -1.03%, changed from $24.35 before the earnings release to $24.10 the day after.

When is Vera Therapeutics, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for Feb 24, 2026.

What are the forecasts for Vera Therapeutics, Inc. Class A Common Stock's next earnings report?

Based on 14 analysts, Vera Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$1.30 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.